IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS

被引：0
|
作者：
Escobar, Miguel [1 ]
Agrawal, Neha [2 ]
Chatterjee, Sagnik [2 ]
Bhattacharya, Swastik [2 ]
Caicedo, Jorge [3 ]
Bullano, Michael [3 ]
Schultz, Robert G. [3 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[2] Complete HEOR Solut, New Wales, PA USA
[3] Takeda Pharmaceut USA Inc, Lexington, MA USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E34 / E34
页数：1
相关论文
共 50 条
  • [41] Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement
    Santagostino, Elena
    Elisa Mancuso, Maria
    Novembrino, Cristina
    Solimeno, Luigi Piero
    Tripodi, Armando
    Peyvandi, Flora
    HAEMATOLOGICA, 2019, 104 (08) : E380 - E382
  • [42] Clinical Outcomes of Noninhibitor Patients with Hemophilia a Switching from Prophylaxis with Factor VIII to Emicizumab: A Meta-Analysis of Real-World Evidence Studies
    Escobar, Miguel A.
    Fan, Qi Angela
    Mokdad, Ali G.
    Tarantino, Michael D.
    Burgess, Benjamin
    Hawe, Emma
    Fernandez, Maria
    Bullano, Michael
    BLOOD, 2023, 142
  • [43] Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab
    Lee, Min Young
    Lee, Woo In
    Kang, So Young
    Kim, Myeong Hee
    Park, Young Shil
    ANNALS OF LABORATORY MEDICINE, 2023, 43 (01) : 96 - 99
  • [44] The economic impact of factor VIII inhibitors in patients with hemophilia.
    Bohn, RL
    Aledort, LM
    Putnam, KG
    Ewenstein, BM
    Avorn, J
    BLOOD, 2000, 96 (11) : 434A - 435A
  • [45] IMPACT ON PRODUCTIVITY ASSOCIATED WITH THE USE OF EMICIZUMAB IN PROPHYLAXIS FOR HEMOPHILIA A WITH INHIBITORS IN COLOMBIA
    Moreno, N. A.
    Munoz-Bedoya, A.
    VALUE IN HEALTH, 2019, 22 : S846 - S846
  • [46] Factor VIII inhibitors in patients with hemophilia A
    Ören, H
    Yaprak, I
    Irken, G
    ACTA HAEMATOLOGICA, 1999, 102 (01) : 42 - 46
  • [47] Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe
    Mancuso, Maria Elisa
    Castaman, Giancarlo
    Pochopien, Michal
    Aballea, Samuel
    Drzewiecka, Aleksandra
    Hakimi, Zalmai
    Nazir, Jameel
    Fatoye, Francis
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1068 - 1075
  • [48] Cost-Effectiveness of Emicizumab for Prophylaxis in People with Severe Hemophilia A without Inhibitors
    Decker-Palmer, Marquita
    Lin, Chia-Wei
    Wilson, Michele
    McDade, Cheryl
    Bawa, Komal
    Kowal, Stacey
    Ravelo, Arliene
    Yu, Elaine
    Ko, Richard H.
    BLOOD, 2022, 140 : 13041 - 13042
  • [49] Surgery-associated factor VIII inhibitors in patients without hemophilia
    Alumkal, J
    Rice, L
    Vempathy, H
    McCarthy, JJ
    Riggs, SA
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1999, 318 (05): : 350 - 352
  • [50] Factor VIII inhibitors in hemophilia a patients with different treatment modalities
    Abdel-Halim, Afifi O.
    Abdul-Azeem, Argoon S.
    Abdel-Rahman, Ahmad Y.
    Thabet, N. M.
    Abdul-All, R. F.
    Mohamed, G. G.
    Thabet, A. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 100 - 100
12345